200 related articles for article (PubMed ID: 36467125)
21. Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials.
Zazula R; Husain MI; Mohebbi M; Walker AJ; Chaudhry IB; Khoso AB; Ashton MM; Agustini B; Husain N; Deakin J; Young AH; Berk M; Kanchanatawan B; Ng CH; Maes M; Berk L; Singh AB; Malhi GS; Dean OM
Aust N Z J Psychiatry; 2021 Aug; 55(8):784-798. PubMed ID: 33092404
[TBL] [Abstract][Full Text] [Related]
22. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
[TBL] [Abstract][Full Text] [Related]
23. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
24. Inflammation and depression treatment response to electroconvulsive therapy: Sex-specific role of interleukin-8.
Kruse JL; Olmstead R; Hellemann G; Wade B; Jiang J; Vasavada MM; Brooks Iii JO; Congdon E; Espinoza R; Narr KL; Irwin MR
Brain Behav Immun; 2020 Oct; 89():59-66. PubMed ID: 32479994
[TBL] [Abstract][Full Text] [Related]
25. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial.
Savitz J; Preskorn S; Teague TK; Drevets D; Yates W; Drevets W
BMJ Open; 2012; 2(1):e000643. PubMed ID: 22357572
[TBL] [Abstract][Full Text] [Related]
26. Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial.
Husain MI; Chaudhry IB; Khoso AB; Husain MO; Rahman RR; Hamirani MM; Hodsoll J; Carvalho AF; Husain N; Young AH
BJPsych Open; 2019 Jan; 5(1):e13. PubMed ID: 30762508
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of eicosapentaenoic acid in inflammatory depression: study protocol for a match-mismatch trial.
Suneson K; Ängeby F; Lindahl J; Söderberg G; Tjernberg J; Lindqvist D
BMC Psychiatry; 2022 Dec; 22(1):801. PubMed ID: 36536364
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-8 and lower severity of depression in females, but not males, with treatment-resistant depression.
Kruse JL; Olmstead R; Hellemann G; Breen EC; Tye SJ; Brooks JO; Wade B; Congdon E; Espinoza R; Narr KL; Irwin MR
J Psychiatr Res; 2021 Aug; 140():350-356. PubMed ID: 34139457
[TBL] [Abstract][Full Text] [Related]
29. Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial.
Dean OM; Maes M; Ashton M; Berk L; Kanchanatawan B; Sughondhabirom A; Tangwongchai S; Ng C; Dowling N; Malhi GS; Berk M
Clin Psychopharmacol Neurosci; 2014 Dec; 12(3):180-8. PubMed ID: 25598820
[TBL] [Abstract][Full Text] [Related]
30. Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD.
Gregg LP; Carmody T; Le D; Bharadwaj N; Trivedi MH; Hedayati SS
Kidney360; 2020 Jun; 1(6):436-446. PubMed ID: 35368605
[TBL] [Abstract][Full Text] [Related]
31. Apparent Lack of Benefit of Combining Repetitive Transcranial Magnetic Stimulation with Internet-Delivered Cognitive Behavior Therapy for the Treatment of Resistant Depression: Patient-Centered Randomized Controlled Pilot Trial.
Adu MK; Shalaby R; Eboreime E; Sapara A; Lawal MA; Chew C; Daubert S; Urichuck L; Surood S; Li D; Snaterse M; Mach M; Chue P; Greenshaw AJ; Agyapong VIO
Brain Sci; 2023 Feb; 13(2):. PubMed ID: 36831836
[No Abstract] [Full Text] [Related]
32. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.
Bekhbat M; Chu K; Le NA; Woolwine BJ; Haroon E; Miller AH; Felger JC
Psychoneuroendocrinology; 2018 Dec; 98():222-229. PubMed ID: 30249443
[TBL] [Abstract][Full Text] [Related]
33. Inflammation and Improvement of Depression Following Electroconvulsive Therapy in Treatment-Resistant Depression.
Kruse JL; Congdon E; Olmstead R; Njau S; Breen EC; Narr KL; Espinoza R; Irwin MR
J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29489077
[TBL] [Abstract][Full Text] [Related]
34. Effect of Zishen pingchan granules combined with pramipexole on serum BDNF, IL-1β, IL-6, CRP, TNF-α levels in depressed patients with Parkinson's disease: Results of a randomized, double-blind, controlled study.
Ning H; Zhou H; Yang N; Ren J; Wang H; Liu W; Zhao Y
Exp Gerontol; 2023 Oct; 182():112295. PubMed ID: 37734668
[TBL] [Abstract][Full Text] [Related]
35. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
36. Sex differences in circulating inflammatory mediators as a function of substance use disorder.
May AC; Burrows K; Figueroa-Hall LK; Kirlic N; White EJ; Smith R; Ekhtiari H; Paulus MP; Savitz J; Stewart JL;
Drug Alcohol Depend; 2021 Apr; 221():108610. PubMed ID: 33631550
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials.
Qiu Y; Duan A; Yin Z; Xie M; Chen Z; Sun X; Wang Z; Zhang X
Front Psychiatry; 2023; 14():1139273. PubMed ID: 37342175
[TBL] [Abstract][Full Text] [Related]
38. Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response.
Walker AJ; Mohebbi M; Maes M; Berk M; Walder K; Bortolasci CC; Liu ZS; Ng CH; Ashton MM; Berk L; Singh AB; Malhi GS; Dean OM
Brain Behav Immun Health; 2023 Feb; 27():100581. PubMed ID: 36632339
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
[TBL] [Abstract][Full Text] [Related]
40. Baseline serum C-reactive protein levels may predict antidepressant treatment responses in patients with major depressive disorder.
Zhang J; Yue Y; Thapa A; Fang J; Zhao S; Shi W; Yang Z; Li Y; Yuan Y
J Affect Disord; 2019 May; 250():432-438. PubMed ID: 30878656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
